Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme

AstraZeneca

Status: Completed

Conditions: Schizophrenia

Study type: Observational

Funder types: Industry

Identifiers

NCT00921362

NIS-NRO-SER-2006/2

SER-01-S-06

Details and patient eligibility

About

Patients eligible for entry into the study have a diagnosis of schizophrenia defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and of a chronic or sub-chronic nature.The primary purpose of the study is to observe symptoms changes over 6 months in schizophrenia in patients treated with Seroquel; additionally disease severity and treatment compliance are followed

Enrollment: 1,387 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• To assess at baseline and after treatment administration the severity of the illness in patients with schizophrenia, using the scores obtained after the application of the CGI scale
• To assess the changes in symptoms of patients treated with Seroquel for 24 weeks, using BPRS (Brief Psychiatry Rating Scale) as measuring tool

Exclusion criteria

• All the patients who have a known hypersensitivity to Seroquel /quetiapine or any of its excipients will not be included in this study.

Trial design

1,387 participants in 1 patient group

1

Description:

Schizophrenia patients under Seroquel treatment